{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix U: Lactation Notification Form', 'Amgen Proprietary Confidential', 'AMGEN', 'Lactation Notification Form', \"Please refer to your site's Lactation Notification Form for Amgen Safety's Country Fax Number\", \"and if Fax is unavailable, Amgen Safety's Country email address.\", '1. Case Administrative Information', 'Protocol/Study Number: CC-10004-PSOR-020 (Aptemuliaat/Otezia)', 'study Design:', 'Interventional', 'Observational (If Observational:', 'Prospective', 'Retrospective)', '2. Contact Information', 'Investigator Name', 'Site #', 'Phone (', ')', 'Fax (', ')', 'Emall', 'Institution', 'Address', '3. Subject Information', 'subject ID #', 'Subject age (at onset):', '(in years)', '4. Amgen Product Exposure', 'Dose at time of', 'Amgen Product', 'Frequency', 'Route', 'start Date', 'breast feeding', 'mm', '/dd', 'how', 'Was the Amgen product (or study drug) discontinued?', 'Yes', 'No', 'If yes, provide product (or study drug) stop date: mm', '/dd', 'Did the subject withdraw from the study?', 'Yes', 'No', '5. Breast Feeding Information', 'Did the mother breastfeed or provide the infant with pumped breast milk while actively taking an Amgen product? Yes', 'No', 'If No, provide stop date: mm', '/dd', 'Infant date of birth: mm', '(dd', '200%', 'Infant gender:', 'Female', 'Male', 'Is the infant healthy?', 'Yes', 'No', 'Unknown', 'N/A', 'If any Adverse Event was experienced by the mother or the infant, provide brief details:', 'Form Completed by', 'Print Name:', 'Title:', 'Signature:', 'Date:', 'FORM-115201', 'Version 1.0', 'Effective Date: 24-Sept-2018', 'Confidential and Proprietary', '99', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Celgene', 'Celgene Signing Page', 'This is a representation of an electronic record that was signed electronically in Livelink.', 'This page is the manifestation of the electronic signature(s) used in compliance with', 'the organizations electronic signature policies and procedures.', 'UserName:', 'Title: Vice President and Head of Immunology & Fibrosis Clinical Develo', 'Date: Tuesday, 05 May 2020, 08:23 AM Eastern Daylight Time', 'Meaning: Approved, no changes necessary.', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Summary of Changes CC-10004-PSOR-020', 'Amgen Inc.', '- SUMMARY OF CHANGES- -', 'A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-', 'BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT', 'OF APREMILAST (CC-10004) ON QUALITY OF LIFE,', 'EFFICACY, AND SAFETY IN SUBJECTS WITH', 'MANIFESTATIONS OF PLAQUE PSORIASIS AND IMPAIRED', 'QUALITY OF LIFE', 'AMENDMENT NO. 3', 'INVESTIGATIONAL PRODUCT (IP):', 'Apremilast', 'PROTOCOL NUMBER:', 'CC-10004-PSOR-020', 'ORIGINAL DATE:', '26 SEP 2018', 'AMENDMENT No. 1 DATE:', '17 JAN 2019', 'AMENDMENT No. 2 DATE:', '01 NOV 2019', 'AMENDMENT No. 3 DATE:', '01 MAY 2020', 'EudraCT NUMBER:', '2018-002850-58', 'IND NUMBER:', '070270', 'NTC NUMBER:', 'NCT03774875', 'Contact Information:', 'Name:', ', MD', 'Title:', 'Senior Director, Global Development', 'Address:', 'Amgen Inc,', 'Amgen Center Dr, Thousand Oaks, CA 91320', 'USA', 'Phone:', 'E-mail:', 'Note: Only call Amgen Medical Information, if you are not able to reach the Clinical Research', 'Physician(s) or Medical Monitor or designee for emergency calls.', 'Amgen Medical Information: -800-77-AMGEN (1-800-772-6436)', 'CONFIDENTIALITY NOTICE', 'This document contains confidential information of Amgen. This document must not be disclosed to', 'anyone other than the site study staff and members of the institutional review board/independent ethics', 'committee/institutional scientific review board or equivalent. The information in this document cannot', 'be used for any purpose other than the evaluation or conduct of the clinical investigation without the', 'prior written consent of Amgen. If you have questions regarding how this document may be used or', 'shared, call the Amgen Medical Information number: 1- - 800-77-AMGEN', 'Confidential and Proprietary', '1', 'CC-10004-PSOR-020 Amendment # 3 Final: 01 May 2020', 'EDMS Doc. Number: 24684941 - 23306134']\n\n###\n\n", "completion": "END"}